New diabetes clinical trial: SGLT2i, Pioglitazone, and Ketone Production in T2D
Published on: July 07, 2025 at 11:00PM
Conditions: Type 2 Diabetes
Interventions: Drug: Empagliflozin 25 MG plus Pioglitazone placebo; Drug: Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo; Drug: Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d); Drug: Pioglitazone placebo + Empagliflozin placebo
Sponsors: The University of Texas Health Science Center at San Antonio; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
https://ift.tt/G1dIwyb
Conditions: Type 2 Diabetes
Interventions: Drug: Empagliflozin 25 MG plus Pioglitazone placebo; Drug: Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo; Drug: Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d); Drug: Pioglitazone placebo + Empagliflozin placebo
Sponsors: The University of Texas Health Science Center at San Antonio; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
https://ift.tt/G1dIwyb
Comments
Post a Comment